This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/mixture/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/chemspider/
n20http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/pharmgkb/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/bindingdb/
owlhttp://www.w3.org/2002/07/owl#
n21http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01325/identifier/drugbank/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01325
rdf:type
n3:Drug
n3:description
Quinethazone (INN, brand name Hydromox) is a thiazide diuretic used to treat hypertension. Common side effects include dizziness, dry mouth, nausea, and low potassium levels.
n3:group
approved
n3:indication
Used to treat hypertension.
owl:sameAs
n20:DB01325 n23:DB01325
dcterms:title
Quinethazone
adms:identifier
n10:PA164760863 n11:46507280 n12:Quinethazone n13:6307 n14:25898 n15:C07342 n16:D00461 n17:6068 n18:DB01325
n3:mechanismOfAction
As a diuretic, quinethazone inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like quinethazone also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of quinethazone is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
n3:synonym
Quinetazona Quinethazonum Chinethazonum Chinetazone Quinethazon Hydromox
n3:foodInteraction
Take with food to increase bioavailability.
n3:mixture
n6:271B6555-363D-11E5-9242-09173F13E4C5
n21:hasConcept
n22:M0144624
n3:IUPAC-Name
n4:271B655A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6560-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B655F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B655C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B655D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B655E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6558-363D-11E5-9242-09173F13E4C5 n4:271B6570-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6559-363D-11E5-9242-09173F13E4C5 n4:271B6556-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6557-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:C03BA02
n3:H-Bond-Acceptor-Count
n4:271B6566-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6567-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6561-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6562-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6564-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6563-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6565-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
73-49-4
n3:category
n3:Bioavailability
n4:271B656C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B656E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B656F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6571-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B656B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B656A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B656D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B655B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6568-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6569-363D-11E5-9242-09173F13E4C5